Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Down 1.4%

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) was down 1.4% during mid-day trading on Monday . The company traded as low as $2.79 and last traded at $2.89. Approximately 207,775 shares changed hands during trading, a decline of 77% from the average daily volume of 901,097 shares. The stock had previously closed at $2.93.

A number of analysts recently issued reports on UNCY shares. Benchmark started coverage on shares of Unicycive Therapeutics in a report on Tuesday, August 17th. They set a “buy” rating for the company. Roth Capital started coverage on shares of Unicycive Therapeutics in a report on Monday, August 9th. They set a “buy” rating and a $13.50 price objective for the company.

The firm has a 50 day moving average price of $2.89.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Monday, August 16th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts anticipate that Unicycive Therapeutics, Inc. will post -0.45 earnings per share for the current year.

Unicycive Therapeutics Company Profile (NASDAQ:UNCY)

Unicycive Therapeutics Inc is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company’s lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc is based in LOS ALTOS, Calif.

Featured Story: What economic reports are most valuable to investors?

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.